Contents

Message from the Director ......................................................... 2
Research Initiatives ........................................................................ 3
Patient Care .................................................................................. 6
Education ....................................................................................... 8
BTC Research Grant Recipients .................................................. 9
Measuring Our Success ............................................................... 10
BTC Leadership ............................................................................. 11
2007–2008 Publications ............................................................... 12
Clinical Trials ............................................................................... 21
Honors and Awards ....................................................................... 23
Message from the Director

Brain tumors present a difficult therapeutic challenge. Nearly 22,000 people in the United States will learn this year that they have cancer of the brain or spinal cord, and some 13,000 will die. In order for us to make progress against these diseases, a multidisciplinary approach to understanding them is critical — one that brings basic science researchers delving into the molecular underpinnings of brain tumors together with clinical investigators seeking to evaluate new treatments for these cancers. That is exactly the approach taken by the Brain Tumor Center (BTC) at Memorial Sloan-Kettering Cancer Center.

The mission of this multidisciplinary and multidepartmental center is to promote innovative clinical, translational, and basic science research related to primary brain tumors as well as those that spread to the brain. The BTC is a center without walls, an interactive and supportive environment in which 60 diverse and talented scientists and physicians collaborate to translate preclinical advances made in the laboratory into new ways to improve the care of patients with brain tumors. We also partner with neighboring investigators at The Rockefeller University and Weill Medical College of Cornell University to advance our progress.

In our first 18 months, the BTC has focused on building infrastructure and setting a disciplined budget, raising funds for novel research projects, conducting preclinical studies and clinical trials, and educating fellows and junior faculty. We have fostered interaction among our members through seminars and workgroup meetings. In all of these efforts, we are fortunate to have the support of generous donors who have been such strong advocates for the advancement of brain tumor research. The Simons Foundation in particular has allowed the BTC to get off to a very strong start. In addition, the Kirby Foundation has funded our “in house” seed grants to young investigators. William and Charlotte Ford have made our intraoperative MRI suite a reality, and the Litwin Foundation and Bruce Ratner have given us the financial strength to become one of the world’s leading brain tumor centers in a very short time period.

The multidisciplinary approach taken by the BTC builds on the tradition of Memorial Sloan-Kettering Cancer Center, which for decades has united basic scientists with clinical researchers in a shared quest to understand and conquer cancer. Today Memorial Hospital’s Disease Management Teams are more powerful than the sums of their parts. And investigators at the Sloan-Kettering Institute (SKI) are using the latest molecular tools to clarify the fundamental mechanisms through which normal cells operate in an effort to understand what goes wrong to produce cancer.

The BTC is well poised to unify the talents of investigators both in the laboratory and in the clinic to enrich the lives of patients with brain tumors, as well as their families and friends. I hope as you read this progress report you’ll get a sense of the cautious optimism we are feeling as we look to a brighter future for people affected by these diseases.

Eric Holland, MD, PhD
Director, Brain Tumor Center
Emily Tow Jackson Chair in Oncology
Research Initiatives

A Translational Approach

BTC researchers are elucidating the cascade of genetic events that promote tumor development and growth, with the goal of translating newfound understanding into novel treatment strategies. Critical to the development of new therapies are preclinical studies in animal models. These models allow researchers to investigate the genetic causes of brain tumors and to create and assess potential treatments.

One example of this translational approach began in the laboratory of Eric Holland, MD, PhD. He and his team created realistic mouse models of several gliomas — including glioblastoma, the most lethal form of brain tumor in people. In 2000, Dr. Holland demonstrated that a signaling pathway containing the kinase Akt (a type of enzyme) was activated in human gliomas and contributed to the formation of these tumors. This work built on earlier observations by investigators in other labs that showed that a tumor suppressor gene called PTEN was frequently mutated in gliomas, and that the Akt pathway was activated by the loss of PTEN.

Dr. Holland’s hypothesis that the activation of Akt was crucial for the formation of gliomas was confirmed by the modeling his laboratory did in mice. Some time later, he and his colleagues were approached by a small pharmaceutical company with a drug that blocks the Akt pathway. Today, MSKCC neuro-oncologist Andrew B. Lassman, MD, is leading a Phase II clinical trial of the drug sorafenib to evaluate its activity against recurrent or progressive gliomas. Moreover, radiologist Michelle S. Bradbury, MD, PhD, is using animal models to develop ways to image a tumor’s response to the drug.

“In a rational attack against gliomas, we moved from the discovery of a therapeutic target, through animal modeling and preclinical studies, and into clinical trials in patients to evaluate a new agent with the potential to work against its target,” explained Dr. Holland. “This is the way drug discovery now happens.”

Ingo Mellinghoff, MD, came to MSKCC from the University of California, Los Angeles, in 2007. He is also a member of MSKCC’s Human Oncology and Pathogenesis Program (HOPP), whose faculty works at the interface of the laboratory and the clinic. Dr. Mellinghoff is designing clinical trials of drugs that interfere with the fundamental genetic aberrations that stimulate tumor cells to grow.

“This approach is a departure from traditional clinical drug development, which often does not consider the genetic heterogeneity of tumors within the same disease. Dr. Mellinghoff explained, new technologies have empowered us to look at tumor cells at incredibly high resolution, and we can now focus on molecular subgroups of tumors and evaluate the effects of drugs on signaling networks within tumor tissue. “What my colleagues and I will be doing is to get a much...
The emergence and integration of genomics (the identification of genes and their functions) into clinical practice has helped to drive this work. The Brain Tumor Center maintains a brain tumor tissue and serum bank, which facilitates the identification of tumor markers that may be used to diagnose tumors or predict their aggressiveness.

“Looking at cancer as a genetic disease — the ability to detect the presence or absence of specific mutations in tumors — has allowed us to think about this sort of ‘personalized medicine,’” Dr. Mellinghoff noted. Because he analyzes brain tumor tissue, it is essential that neurosurgeons remove tumor tissue very carefully. “Neurosurgeons play a big role in the success of our efforts,” he added.

**From the Laboratory to the Clinic**

Clinical trials of new preventive, diagnostic, and treatment approaches are critical for progress to be made against cancer. Memorial Sloan-Kettering is a national leader in evaluating investigational drugs with the potential to improve the outcome of patients with all types of cancer, including brain tumors. Clinical research in the BTC combines the efforts of laboratory and clinical investigators to develop and assess new drugs for people with brain tumors.

Many of these therapies are developed in the laboratory under the guidance of neuro-oncologists with the express intent of evaluating them in clinical trials. Some of these studies have surgical components — for example, the drugs are given for a week prior to brain tumor surgery, and their effects on tumors are measured in the tissue samples that are removed.

“The BTC provides a framework for a scientist to say, ‘We have a great idea in our laboratory,’ and for a clinician to learn about such an idea and work with that scientist to design a clinical trial,” said Lauren Abrey, MD, Director of Clinical Research for the Department of Neurology. “The BTC is an important catalyst for this sort of interaction.”

“Seeing patients is a most gratifying human experience,” added Dr. Mellinghoff. “It points you toward critical questions to be addressed in the laboratory, and builds strong relationships with other oncologists, surgeons, pathologists, and radiologists. This is what the BTC is all about: to attack the disease from many different directions and with many minds at work.”

Memorial Sloan-Kettering has a broad spectrum of clinical trials for patients with brain tumors. MSKCC is a member of the North American Brain Tumor Consortium, a group devoted to early-phase clinical trials in patients with gliomas, sponsored by the National Cancer Institute (NCI), and is also a participant in several Radiation Therapy Oncology Group (RTOG) studies. The RTOG is a multi-institutional NCI-funded research group.
The number of MSKCC protocols related to brain tumors has grown significantly in the past seven years, from 18 protocols to more than 60. Most of them are therapeutic protocols designed to evaluate new drug and radiation therapy combinations to improve the quality of life and prolong the lives of patients. For a listing of current clinical trials related to brain tumors, visit Memorial Sloan-Kettering’s Web site at www.mskcc.org/braintumors.

Therapeutic areas currently under study include:

**Novel Chemotherapy Agents:** Researchers are evaluating new types of drugs that block or interfere with cancer cell growth, particularly for the treatment of malignant brain tumors that often recur or continue to grow despite therapy. Among these agents are:

- angiogenesis inhibitors, which prevent the growth of new blood vessels that tumors need to receive nutrients and to grow and spread
- growth factor inhibitors, which block proteins that fuel tumor growth (such as epidermal growth factor) by preventing them from reaching their receptors
- drugs that reduce the ability of cells that have genetic mutations associated with cancer to multiply and divide

**Combined Modality Therapy:** Multimodality therapy — the use of more than one means of killing cancer cells — is commonly used to treat cancer. By combining radiation therapy with one or more chemotherapy drugs, for example, investigators hope to kill more tumor cells and overcome the drug resistance that can develop with single therapies. Therapies being evaluated for brain tumors include angiogenesis inhibitors such as bevacizumab combined with irinotecan, temozolomide, and other anticancer drugs. Other drugs have the potential to enhance the therapeutic effect of radiation therapy by increasing the sensitivity of tumor tissue to radiation while leaving healthy tissue unharmed.

**Immunotherapy:** Immunotherapeutic approaches harness the power of the immune system to fight cancer. BTC investigators are evaluating monoclonal antibodies designed to provoke a patient’s immune system to recognize and attack brain tumor cells. These antibodies are created in the laboratory and attach to a specific protein on the surface of a tumor cell. In one approach, a monoclonal antibody is tagged with a radioactive isotope that identifies and kills tumor cells.
Patient Care

Patients with brain tumors receive multidisciplinary care from a team of Memorial Sloan-Kettering’s brain tumor specialists that combines the expertise of many healthcare professionals. The team features experts dedicated to the care of children and adults with brain tumors and includes neurosurgeons, neuro-oncologists, neuroradiologists, neuroradiation oncologists, neuropathologists, neuropsychologists, neurosurgery physician assistants, neurosurgery nurses, nurse practitioners, neuro-oncology clinical and research nurses, research managers, social workers, and specialists in integrative medicine, pain and palliative care, and endocrinology.

This collaboration ensures that patients who need several different therapies receive the most appropriate combination of treatments. Moreover, because our doctors are also clinical investigators, patients have access to the newest treatment approaches as well as to clinical trials of innovative therapies.

Talent Meets Technology

The brain is the most complicated organ in the body, controlling our every thought, movement, and function. That’s why neurosurgeons try to carefully remove brain tumor tissue while leaving the patient as functional as possible, without impairing senses such as speech and motor functions such as walking or fine movements.

MSKCC surgeons operate on more brain tumors in a year than most surgeons perform in a lifetime. This surgical expertise, combined with advanced technologies, enables the BTC to treat a wide range of tumors with the most advanced therapies available.

Functional MRI

To enhance the likelihood of a successful operation, Memorial Sloan-Kettering neurosurgeons use a variety of state-of-the-art navigational approaches to map each patient’s brain. For example, surgeons can use an intraoperative mapping technique that allows them to identify crucially important areas of the brain in real time, so that they can preserve them as much as possible.

Functional magnetic resonance imaging (fMRI) is a painless imaging technology used to identify the location of functional areas of the brain — such as those responsible for movement or speech. The exact location of these areas varies among individuals, particularly when a large tumor has developed in the brain.

Functional MRI supplements standard MRI images of the brain by indicating areas of increased activity that correspond to specific tasks the patient performs. During an fMRI exam, a neuropsychologist asks the patient to tap fingers, count, or describe images. The areas of the brain corresponding to each of these tasks “light up” on an fMRI scan, enabling the surgeon to plan surgery accordingly, optimizing the patient’s opportunity for the best quality of life after the operation.

FAST FACTS

Patients with brain tumors can receive treatment at a variety of MSKCC locations, including Memorial Hospital (1275 York Avenue, New York, New York), the Rockefeller Outpatient Pavilion (on Third Avenue at 53rd Street), and our regional care network facilities in Basking Ridge, New Jersey, and Commack, Long Island.

In 2007–2008:

- The Department of Neurology averaged 425 new registrations, and about 8,500 total visits
- The Department of Neurosurgery performed an average of 660 surgical procedures
- The Department of Pediatrics cared for an average of 75 patients with central nervous system tumors
- The Department of Radiation Oncology consulted on the care of an average of 485 patients with brain metastases and an average of 145 patients with brain tumors
Another navigation technology, called fusion software, allows information obtained during fMRI testing to be integrated into the anatomic MRI scans used for stereotactic surgical navigation. This system can also be used in surgical procedures of the spine.

**Intra-Operative Imaging Suite**

Memorial Sloan-Kettering is one of only a few hospitals in the country with an intra-operative imaging suite equipped with a high-field-strength MRI scanner located right in the operating room. Performing brain tumor surgery in this setting allows the neurosurgeon to reevaluate the tumor with MRI during the operation, thus enabling him or her to operate with increased precision and possibly reducing the need for a second surgery.

**Image-Guided Stereotactic Surgery**

Frameless stereotaxy, a very precise method of operating on deep-seated brain structures, is based on the idea that all points of the brain can be described using a three-dimensional system of coordinates. Using stereotaxy, surgeons can plan operations in advance and also have access to orientation and guidance as the surgery unfolds.

The team directs a wand-like viewing device with a light at its tip at the patient’s brain, and a 3-D image is scanned and projected onto a monitor in the operating room. This image gives the neurosurgeon up-to-the-moment orientation as he or she navigates through healthy tissue to remove the tumor. The neurosurgeon can also use the viewing wand to help track the tumor to its margins (the edges or borders of the tissue removed during surgery) during the operation, increasing the chances for more complete tumor removal.

**Specialized Care for Pituitary Tumors**

Our multidisciplinary approach to the treatment of pituitary tumors within our pituitary clinic brings together neurosurgeons, endocrinologists, neuro-ophthalmologists, skull-base surgeons, radiation oncologists, and neuroradiologists who collaborate to customize a treatment plan for each patient. State-of-the-art diagnostics — including imaging, hormone testing, and visual-field testing — combined with surgery, radiation therapy, and medication — are used to ensure that patients receive the most sophisticated care available.

**Expertise in Spine Oncology**

The Spine Oncology Team is a multidisciplinary group of doctors who work together to diagnose and treat each patient who comes to the Spine Clinic. This approach to cancer care combines the expertise of many doctors within the departments of Anesthesiology, Interventional Radiology, Neurology, Neurosurgery, Orthopaedic Surgery, Radiation Oncology, and Rehabilitation Medicine to ensure that patients who need several different therapies to treat their cancer will receive the safest and most effective combination.
Education

Educating the academic medical leaders of tomorrow is a vital part of MSKCC’s mission. As part of this effort, the BTC features several different levels of training:

**Postdoctoral and Clinical Fellowships**

The BTC supports the teaching of fellows in basic science research. We have funded three postdoctoral fellows to train in BTC laboratories:
- Jason Huse, from the Harvard Medical School, trains in the Department of Neurosurgery
- Guillaume Normand, from the Harvard Medical School, trains in the Molecular Pharmacology and Chemistry Program in SKI
- Yuhui Liu, from the Beijing Medical School, trains in the Molecular Biology Program in SKI

As part of our clinical program, the Departments of Neurology, Neurosurgery, and Pediatrics educate clinical fellows seeking to specialize in the care of patients with brain tumors.

**Medical Student Training**

As part of MSKCC’s Medical Student Summer Fellowship Program, students interact with oncologists who specialize in different aspects of brain tumor research and treatment. Students have the opportunity to observe surgery and participate in clinics for brain tumor patients.

Eleven students participated in the Brain Tumor Center Summer Exposure Program in 2008 and were mentored by BTC faculty. These students, who came from various medical schools in the northeastern United States, conducted brain-related research projects focusing on areas such as stem cell research, DNA damage, the importance of functional MRI, and outcomes for glioblastoma patients.

**Seminars**

The BTC has developed a seminar series in which faculty members both within and outside MSKCC make presentations focusing on various brain tumor topics. The series is the first of its kind to bring together brain tumor specialists from multiple disciplines. Viviane Tabar, MD, an Attending Surgeon in the Department of Neurosurgery, facilitates the series.

To refer a patient to the Brain Tumor Center, please call 212-639-6661 or e-mail btc@mskcc.org
BTC Research Grant Recipients

2007

Michael McDevitt, PhD
Assistant Attending, Department of Medicine
Targeting tumor vasculature with a self-assembling synthetic infarct

Andrew Lassman, MD
Assistant Attending, Department of Neurology
Targeting glioblastoma stem cells with Akt inhibition and radiation

Adilia Hormigo, MD, PhD
Assistant Attending, Department of Neurology
Understanding the role of CD133+ stem cells in the brain

Michelle Bradbury, MD, PhD
Assistant Attending, Department of Radiology
Dynamic PET imaging of tumor growth and early response to targeted signaling inhibitors in genetically engineered mouse models

Luca Cartegni, PhD
Assistant Member, Molecular Pharmacology and Chemistry Program (SKI)
Profiling, characterization, and therapeutic modulations of aberrant alternative RNA splicing in gliomas

Daniel Ciznadija, PhD
Research Fellow, Molecular Biology Program (SKI)
Dissection of the oncogenic functions of the cyclin-dependent kinase inhibitor p21 mediating PDGF-directed gliomagenesis

2008

Kathryn Beal, MD
Assistant Attending, Department of Radiation Oncology

Robert Young, MD
Assistant Attending, Department of Radiology
Using advanced MR imaging to determine high risk areas in patients with malignant high grade gliomas and potential changes in radiation therapy

Oren Becher, MD
Instructor, Department of Pediatrics
Using RCAS tv-a system to model brainstem gliomas

Bipin Bhatia, PhD
Research Fellow, Cancer Biology and Genetics Program (SKI)
Tumor suppressor TSC2 inactivation and p27 mislocalization in brain development and medulloblastoma

Cameron Brennan, MD
Assistant Attending, Department of Neurosurgery
A microarray-based molecular diagnostic panel for glioma

Steven Foster, PhD
Research Fellow, Molecular Biology Program (SKI)
The link between covalent protein-DNA lesion formation and repair in neurons and medulloblastoma development

Ruimin Huang, PhD
Fellow, Department of Neurology
Non-Invasive bioluminescence imaging of antiangiogenic effects on gliomas in VEGF/VEGFR2 reporter mouse models

Xinjiang Wang, PhD
Research Fellow, Cell Biology Program (SKI)
NEDD4-1 as a gliomagenic oncogene and drug target for treatment of brain tumor

Grant Review Committee: Lisa DeAngelis, Philip Gutin, Desert Horse-Grant, Johanna Joyce, Andrew Koff, Steven Larson, Joan Massagué, Neal Rosen, Charles Savvyers

To refer a patient to the Brain Tumor Center, please call 212-639-6661 or e-mail btc@mskcc.org
Measuring Our Success

Our Program Development Office has made the vision of the BTC a reality. The office includes a program administrator, research manager, research coordinator, project coordinator, programmer analyst, and administrative assistant, and in the laboratory, a senior scientist and laboratory technician.

The Program Development Office has collected data to measure the impact of our members’ efforts on brain tumor research — investigations that are heavily dependent on donations from generous foundations and individuals as well as grants from different agencies, in particular, the National Institutes of Health (NIH). Last year, we witnessed a 100 percent increase in our NIH funding compared with funding five years ago.

The progress in our research is evidenced not only by this funding increase but also by publications authored by BTC members. As depicted in the sidebar, our publications have more than doubled, and our collaborations have approximately doubled in the past seven years. We are now focused on further increasing these numbers and fostering new collaborations.
Brain Tumor Center Leadership

EXECUTIVE BOARD

Director

Eric Holland, MD, PhD
Vice Chair, Department of Surgery
Attending Surgeon, Department of Neurosurgery
Member, Cancer Biology and Genetics Program
Emily Tow Jackson Chair in Oncology

Executive Co-Directors

Lisa DeAngelis, MD
Chair, Department of Neurology
Lillian Rojtman Berkman Chair in Honor of Jerome B. Posner

Philip Gutin, MD
Chair, Department of Neurosurgery
Fred Lebow Chair in Neuro-Oncology

Program Administrator

Desert Horse-Grant

EXTERNAL ADVISORY BOARD

Richard Gilbertson, MD, PhD
Director, Molecular Clinical Trials Core
Co-Leader, Neurobiology and Brain Tumor Program
Department of Developmental Neurobiology Oncology
St. Jude Children’s Research Hospital

Luis Parada, PhD
Chairman, Department of Developmental Biology
Diana and Richard C. Strauss Distinguished Chair in Developmental Biology
Director, Kent Walldrop Center for Basic Research on Nerve Growth and Regeneration
Southwestern Ball Distinguished Chair in Basic Neuroscience Research
University of Texas Southwestern Medical Center

Paul Mischel, MD
Professor, Department of Pathology and Laboratory Medicine
David Geffen School of Medicine
Scientific Director, Sarkaria Biomarkers Program
Co-Director, Cancer Stem Cell Program
UCLA Institute for Stem Cell Biology and Medicine

Jim Rutka, MD, PhD
Chairman, Department of Neurosurgery
Co-Director, Labatt Brain Tumor Research Centre
University of Toronto

To refer a patient to the Brain Tumor Center, please call 212-639-6661 or e-mail btc@mskcc.org
2007–2008 Publications

Abrey LE. Anaplastic oligodendroglialoma. *Curr Neurol Neurosci Rep.* 2007 May;7(3):189-90.

Abrey LE, Louis DN, Paleologos N, Lassman AB, Raizer JJ, Mason W, Finlay J, MacDonald DR, DeAngelis LM, Cairncross G. Survey of treatment recommendations for anaplastic oligodendroglialoma. *Neuro Oncol.* 2007 Jul;9(3):314-8.

Abrey L. Bevacizumab in recurrent malignant glioma. *Curr Neurol Neurosci Rep.* 2008 May;8(3):233-4.

Ahmadi-Zarghami H, Fallah-Tafti S, Behzadnia N, Sharif-Kashani B, Karimi S, Eslampanah S. Photoclinic. Right ventricular myxoma presenting as pulmonary embolism. *Arch Iran Med.* 2007 Apr;10(2):268, 270-1.

Bai G, Sheng N, Xie Z, Bian W, Yokota Y, Benecra R, Kageyama R, Guillemot F, Jing N. Id proteins sustain Hes1 expression to inhibit precocious neurogenesis by releasing the negative autoregulation of Hes1. *Dev Cell.* 2007 Aug;13(2):283-97.

Ban J, Bonifazi P, Pinato G, Broccard FD, Studer L, Torres V, Ruoar ME. Embryonic stem cell-derived neurons form functional networks in vitro. *Stem Cells.* 2007 Mar;25(3):738-49.

Barbashina V, Salazar P, Ladanyi M, Edgar M, Rosenblum MK. Glioneuronal tumor with neuropol-like islands (GNTI): a report of 8 cases with chromosome 1p/19q deletion analysis. *Am J Surg Pathol.* 2007 Aug;31(8):1196-202.

Barberi T, Bradbury M, Dincer Z, Panagiotakos G, Socci ND, Studer L. Derivation of engraftable skeletal myoblasts from human embryonic stem cells. *Nat Med.* 2007 May;13(5):642-8.

Basso N, Achevarria D, Ahn C, Sudarov A, Joyner A, Mason J, Martinez S, Martin G. Specific regions within the embryonic midbrain and cerebellum require different levels of FGF signaling during development. *Development.* 2008 Mar;135(5):889-98.

Bazzoli E, Iwamoto FM, Zelenetz AD, Deangelis LM, Abrey LE. Synchronous presentation of systemic and brain non-Hodgkin lymphoma. *Leuk Lymphoma.* 2008 Dec;49(12):2370-3.

Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. *Proc Natl Acad Sci USA.* 2007 Dec 26;104(52):20932-7.

Becher O, Hambardzumyan D, Fomchenko E, Momota H, Mainwaring L, Bleau A, Katz A, Edgar M, Kenney A, Cordon-Cardo C, Blasberg R, Holland E. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. *Cancer Res.* 2008 Apr 1;68(7):2241-9.

Becher O, Peterson K, Khatua S, Santi M, MacDonald T. IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK. *J Child Neurol.* 2008 Oct;23(10):1205-13.

Benezra R Henke E. Id proteins and Angiogenesis. *Endothelial Biomedicine.* 2007. ISBN 978-0-521-85376-1.

Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart H, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiase RM, Demichelis F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liu L, Mischel PS, Cloughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff IK, Sellers WR. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. *Proc Natl Acad Sci USA.* 2007 Dec 11;104(50):20007-12.

Bilsky MH, Azeem S. The NOMS framework for decision making in metastatic cervical spine tumors. *Curr Opin Ortho.* 2007 18(3):263-9.

Bilsky M, Azeem S. Multiple myeloma: Primary bone tumor with systemic manifestations. *Neurosurg Clin N Am.* 2008 Jan;19(1):31-40.

Bilsky M, Gerszten P, Laufer I, Yamada Y. Radiation for primary spine tumors. *Neurosurg Clin N Am.* 2008 Jan;19(1):119-23.

Blaess S, Stephen D, Joyner A. Gli3 coordinates three-dimensional patterning and growth of the tectum and cerebellum by integrating Shh and Fgf8 signaling. *Development.* 2008 Jun;135(12):2093-103.

Bleau AM, Holland EC. Trapping the mouse genome to hunt human alterations. *Proc Natl Acad Sci USA.* 2007 May 8;104(19):7737-8.
Bleau A, Howard B, Taylor L, Gursel D, Greenfield J, Lim Tung H, Holland E, Boockvar J. New strategy for the analysis of phenotypic marker antigens in brain tumor-derived neurospheres in mice and humans. Neurosurg Focus. 2008;24(3-4):E28.

Bradbury MS, Panagiotakos G, Chan BK, Tomishima M, Zanonzico P, Vider J, Ponomarev V, Studer L, Tabar V. Optical bioluminescence imaging of human ES cell progeny in the rodent CNS. J Neurochem. 2007 Sep;102(6):2029-39.

Bradbury M, Hambardzumyan D, Zanonzico P, Schwartz J, Cai S, Burnazi E, Longo V, Larson S, Holland E. Dynamic small-animal PET imaging of tumor proliferation with 3'-Deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas. J Nucl Med. 2008 Mar;49(3):422-9.

Bradley SV, Holland EC, Liu GY, Thomas D, Hyun TS, Ross TS. Huntegtingp interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. Cancer Res. 2007 Apr 15;67(8):3609-15.

Brem S, Bierman P, Black P, Bram H, Chamberlain M, Chocca E, DeAngelis L, Fenstermaker R, Friedman A, Gilbert M, Glass J, Grossman S, Heimberger A, Junck L, Linette G, Loeffler J, Maor M, Moon S, Mrugala M, Nabors L, Newton H, Oliva A, Portnow J, Prados M, Raizer J, Schieve D, Sills A Jr. Central nervous system cancer. J Natl Comp Canc Netw. 2007 Apr;2(3):126-36.

Brennan, C and The Cancer Genome Atlas Research Network (231 multiple equal coauthors). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008 Oct 23;455(7216):1061-8.

Butowski N, Chang S, Junck L, DeAngelis L, Abrey L, Fink K, Cloughesy T, Lamborn K, Salazar A, Prados M. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol. 2009 Jan;91(2):175-82.

Butowski N, Lamborn K, Lee B, Prados M, Cloughesy T, DeAngelis L, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar A, Chang S. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol. 2009 Jan;91(2):183-9.

Carlson MR, Pope WB, Horvath S, Braunstein JG, Nghiemphu P, Tso CL, Mellinghoff IK, Lai A, Liau LM, Mischel PS, Dong J, Nelson SF, Cloughesy TF. Relationship between survival and edema in malignant gliomas: Role of vascular endothelial growth factor and neuronal pentaxin 2. Clin Cancer Res. 2007 May 1;13(9):2592-8.

Chadalavada RS, Korkola JE, Houldsworth J, Olshein AB, Bosl GJ, Studer L, Chaganti RS. Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells. Stem Cells. 2007 Mar;25(3):771-8.

Chang J, Yenice K, Narayana A, Gutin P. Accuracy and feasibility of cone-beam computed tomography for stereotactic radiosurgery setup. Med Phys. 2007 Jun;34(6):2077-84.

Chen C, Hou B, Holodny A. Effect of age and tumor grade on BOLD fMRI in preoperative assessment of glioma patients. Radiology. 2008 Sep;248(3):971-8.

Chen JX, Kula R. “Styloid” syncope. Neurology. 2008 Nov 11;71(20):1649.

Cloughesy T*, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Huseh T, Chen Y, Wang W, Youngkin D, Liu L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koletore M, Trent J, Horvath S, Mischel P*, Mellinghoff I*, Sawyers C* (*corresponding authors). Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008 Jan 22;5(1):e8.

Correa DD, DeAngelis LM, Shi W, Thaler HT, Lin M, Abrey LE. Cognitive functions in low grade gliomas: Disease and treatment effects. J Neurooncol. 2007 Jan;81(2):175-84.

Correa DD, Maron L, Harder H, Klein M, Armstrong C, Calabrese P, Bromberg J, Abrey L, Batchelor T, Schiff D. Cognitive functions in primary central nervous system lymphoma: Literature review and assessment guidelines. Ann Oncol. 2007 Jul;18(7):1145-51.

Correa DD, Shi W, Thaler HT, Cheung AM, Deangelis LM, Abrey LE. Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol. 2008 Feb;86(3):321-7.

Correa D, Ahles T. Neurocognitive changes in cancer survivors. Cancer. 2008 Nov-Dec;114(6):396-400.

Correa D, Rocco-Donovan M, DeAngelis L, Dolgoff-Kaspar R, Iwamoto F, Yahalom J, Abrey L. CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol. 2009 Feb;91(3):315-21.
D’Ambrosio N, Soohoo S, Warshall C, Johnson A, Karimi S. Craniofacial and intracranial manifestations of Langerhans cell histiocytosis: report of findings in 100 patients. AJR Am J Roentgenol. 2008 Aug;191(2):S89-97.

Deng G, Hou B, Holodny A, Cassileth B. Functional magnetic resonance imaging (fMRI) changes and saliva production associated with acupuncture at LI-2 acupuncture point: a randomized controlled study. BMC Complement Altern Med. 2008 Jul 7;8:37.

Desbordes S, Placantonakis D, Ciro A, Socci N, Gabsang Lee G, Djaballah H, Studer L. High-throughput screening assay for the identification of compounds regulating human embryonic stem cells self-renewal and differentiation. Cell Stem Cell. 2008 Jun 5;2(6):602-12.

Dhall G, Finlay J, Dunkel I, Ettinger L, Kellie S, Allen J, Egeler R, Arceci R. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer. 2008 Jan;50(1):72-9.

Dhall G, Grodman H, Ji L, Sands S, Gardner S, Dunkel I, McCowage G, Diez B, Allen J, Gopalan A, Cornelius A, Termuhlen A, Abromowitz M, Sposto R, Finlay J. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols. Pediatr Blood Cancer. 2008 Jun;50(6):1169-75.

Doolittle N, Abrey L, Shenkier T, Siegal T, Bromberg J, Neuwelt E, Soussain C, Jahnke K, Johnston P, Ilerhaus G, Schif D, Batchelor T, Montoto S, Kraemer D, Zucca E. Brain parenchymal involvement as isolated central nervous system (CNS) relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group Report. Blood. 2008 Feb 11;111(4):1085-93.

Du J, Bernasconi P, Clauser K, Mani D, Finn S, Beroukhim R, Burns M, Julian B, Peng X, Hieronymus H, Maglathlin R, Lewis T, Liau L, Nghiempu P, Mellinghoff I, Louis D, Loda M, Carr S, Kung A, Golub T. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol. 2008 Dec 21.

Dudu V, Ramcharan M, Gilchrist M, Holland E, Vazquez M. Liposome delivery of quantum dots to the cytosol of live cells. J Nanosci Nanotechnol. 2008 May;8(5):2293-300.

Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN, Zhang W. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA. 2007 Jul 10;104(28):11736-7.

Edgar MA. The nerve supply of the lumbar intervertebral disc. J Bone Joint Surg Br. 2007 Sep;89(9):1135-9.

Edgar MA, Rosenblum MK. Mixed glioneuronal tumors: recently described entities. Arch Pathol Lab Med. 2007 Feb;131(2):228-33.

Edgar M, Rosenblum M. The differential diagnosis of central nervous system tumors. A critical examination of some recent immunohistochemical applications. Arch Pathol Lab Med. 2008 Mar;132(3):500-9.

Ekenel M, Hormigo A, Peak S, DeAngelis LM, Abrey LE. Capecitabine therapy of the central nervous system metastases from breast cancer. J Neurooncol. 2007 Nov;85(2):223-7.

Ekenel M, Iwamoto F, Ben-Porat L, Panageas K, Yahalom J, DeAngelis L, Abrey L. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer. 2008 Sep 1;113(5):1025-31.

Elkabetz Y, Panagiotakos G, AlShamy G, Socci N, Tabar V, Studer L. Human ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. Genes Dev. 2008 Jan 15;22(2):152-65.

Fangusaro J, Finlay J, Sposto R, Ji L, Saly M, Zacharoulis S, Asgharzadeh S, Abromowitz M, Olsheski R, Halpern S, Dubowry R, Comito M, Diez B, Kellie S, Hukin J, Rosenblum M, Dunkel I, Miller D, Allen J, Gardner S. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. Pediatr Blood Cancer. 2008 Mar;50(2):312-8.

Fangusaro J, Dubowy R, Comito M, Diez B, Kellie S, Hukin J, Rosenblum M, Dunkel I, Miller D, Allen J, Gardner S. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. Pediatr Blood Cancer. 2008 Mar;50(2):312-8.

To refer a patient to the Brain Tumor Center, please call 212-639-6661 or e-mail btc@mskcc.org
Finlay J, Dhall G, Boyett J, Dunkel I, Gardner S, Goldman S, Yates A, Rosenblum M, Stanley P, Zimmerman R, Wallace D, Pollack I, Packer R. Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma. Outcome compared with conventional chemotherapy. A report form the Children’s Oncology Group. Pediatr Blood Cancer. 2008 Dec;51(6):806-11.

Fins JJ, Schiff ND, Foley KM. Late recovery from the minimally conscious state: ethical and policy implications. Neurology. 2007 Jan 23;68(4):304-7.

Fomchenko EI, Holland EC. Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment. Neurosurg Clin N Am. 2007 Jan;18(1):39-58, viii.

Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, Depinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007 Nov 1;21(21):2683-710.

Fury MG, Zahalsky A, Wong R, Venkatraman E, Lis E, Hann L, Aliff T, Gerald W, Fleisher M, Pfister DG. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs. 2007 Apr;25(2):165-72.

Gerstner E, Abrey L, Schiff D, Ferreri A, Lister A, Montoto S, Tsang R, Thiel E, Graus F, Behringer D, Illerhaus G, Weaver S, Wen P, Harris N, Batchelor T. CNS Hodgkin Lymphoma. Blood. 2008 Sep 1;112(5):1658-61.

Gil Z, Patel S, Cantu G, Fliss D, Kowalski L, Singh B, Snyderman C, Kraus D, Shah J; International Collaborative Study Group. Outcome of craniofacial surgery in children and adolescents with malignant tumors involving the skull base: An international collaborative study. Head Neck. 2008 Dec 15.

Gilheeney SW, Lyden DC, Sguero S, Antunes N, Gerald W, Kramer K, Lis E, Meyers P, Rosen N, Thaler HT, Trippett T, Wexler L, Dunkel IJ. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies. Pediatr Blood Cancer. 2007 Sep;49(3):261-5.

Gologorsky Y, DeLaMora P, Souweidane MM, Greenfield JP. Cerebellar cryptococcoma in an immunocompetent child. Case report. J Neurosurg. 2007 Oct;107(4 Suppl):S119-7.

Gilheeney S, Saad A, Chi S, Turner C, Ullrich N, Goumnerova L, Scott R, Marcus K, Lehman L, De Girolami U, Kieran M. Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. J Neurooncol. 2008 Aug;89(1):89-95.

Gorlick RG, Abramson DH, Sowers R, Mazza BA, Dunkel IJ. Impairments in antifolate transport are common in retinoblastoma tumor samples. Pediatr Blood Cancer. 2008 Mar;50(3):579-6.

Greenfield J, Hoffman C, Kuo E, Christos P, Souweidane M. Intraoperative assessment of endoscopic third ventriculostomy success. J Neurosurg Pediatrics. 2008 Nov;2(5):298-303.

Greenfield J, Leng L, Chaudhry U, Brown S, Anand V, Souweidane M, Schwartz T. Combined simultaneous endoscopic transphenoidal and endoscopic transventricular resection of a giant pituitary macroadenoma. Minim Invas Neurosurg. 51:306–309, 2008.

Grimm S, Pulido J, Jahnke K, Schiff D, Hall A, Shenker T, Siegal T, Doolittle N, Batchelor T, Herrlinger U, Newvelt E, Laperriere N, Chamberlain M, Blay J, Ferreri A, Omuro A, Thiel E, Abrey L. Primary intraocular lymphoma: An international primary central nervous system lymphoma lymphoma collaborative group report. Ann Oncol. 2007 Nov;18(11):1851-5.

Groves MD, P dùvalli VK, Chang SM, Conrad CA, Yung WKA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Lamborn KF, Prados MD. A North American Brain Tumor Consortium (NABTC 99-04) Phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007 Feb;81(3):271-7.

Hambardzumyan D, Becher O, Rosenblum M, Pandolfi P, Manova-Todorova K, Holland E. P13K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastomas in vivo. Genes Dev. 2008 Feb 15;22(4):436-48.

Haque S, Law M, Abrey L, Young R. Imaging of lymphoma of the central nervous system, spine and orbit. Radiol Clin North Am. 2008 Mar;46(2):339-81, ix.

Hildebrand J, Gorilia T, Kros J, Afra D, Frenay M, Omuoro A, Stupp R, Lacombe D, Allgeier A, van den Bent M; EORTC Brain Tumour Group investigators. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of an international collaborative study. Eur J Cancer. 2008 Jun;44(9):1210-6.

Hoffman, C, Lis E, Wolden S, Souweidane M. Symptomatic chiari type/malformation after radiation in an infant: Case report. Neurosurgery. 2007 Apr;60(4):E782; discussion E782.
Hoffman CE, Souweidane M. Cerebrospinal fluid-related complications with autologous duraplasty and arachnoid sparing in type I Chiari malformation. *Neurosurgery.* 2008 Mar;62(3 Suppl 1):156-60; discussion 160-1.

Hormigo A, Gutin PH, Rafii S. Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers. *Cancer Cell.* 2007 Jan;11(1):6-8.

Hottinger AF, Khakoo Y. Update on the management of familial central nervous system tumor syndromes. *Curr Neurol Neurosci Rep.* 2007 May;7(3):200-7.

Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. *Neurology.* 2007 Sep 11;69(11):1178-92.

Idowu M, Rosenblum M, Wei X-J, Edgar M, Soslow R. Ependymomas of the central nervous system and adult extra-axial ependymomas are morphologically and immunohistochemically distinct. A comparative study with assessment of ovarian carcinomas for expression of glial fibrillary acidic protein. *Am J Surg Pathol.* 2008 May;32(5):710-8.

Iwamoto FM, Schwartz J, Pandit-Taskar N, Peak S, Divgi CR, Zelenetz AD, Humm J, Abrey LE. Study of radiolabeled indium-111 and yttrium-90 biritumomab truxetan in primary central nervous system lymphoma. *Cancer.* 2007 Dec 1;110(11):2528-34.

Iwamoto F, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, Rosenblum M, Hormigo A. Relevance of chromosomal 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. *J Neurooncol.* 2008 Jul;88(3):293-8.

Iwamoto F, Omuro A, Raizer J, Nolan C, Hormigo A, Lassman A, Gavrilovic I, Abrey L. A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. *J Neurooncol.* 2008 Mar;87(1):85-90.

Iwamoto F, Reiner A, Panageas K, Elkin E, Abrey L. Patterns of care in elderly glioblastoma patients. *Ann Neurol.* 2008 Dec;64(6):628-34.

Kaley T, Abrey L. Glioblastoma: A case-based illustration of recent advances and current challenges. *Case Studies in Glioma, Physicians Education Resource.*

Kim A, Ji L, Balmaceda C, Diez B, Kellie S, Dunkel I, Gardner S, Sposto R, Finlay J. The prognostic value of tumor markers in newly diagnosed patients with primary central nervous system germ cell tumors. *Pediatr Blood Cancer.* 2008 Dec;51(6):768-73.

Klopman J, Tsouris A, Souweidane M. Atraumatic epidural hematoma secondary to a venous sinus thrombosis: a novel finding. *J Neurosurg Pediatrics.* 2008 Dec;2(6):416-9.

Komotar RJ, O’Toole JE, Mocco J, Khandji AG, Keller CE, Connolly ES Jr, Bilsky MH, McCormick PC. Gangliocytoma of the spinal cord. *Neurosurgery.* 2007 May;60(5):895-900.

Kramer K, Humm JL, Souweidane MM, Zanonzico PB, Dunkel IJ, Gerald WL, Khakoo Y, Yeh SD, Yeung HW, Finn RD, Wolden SL, Larson SM, Cheung NK. Targeted radioimmunotherapy for leptomeningeal cancers: Results of a phase I study using Intra-Ommaya 131I-3F8. *J Clin Oncol.* 2007 Dec 1;25(34):5465-70.

Kreisl T, Lassman A, Mischel P, Rosen N, Scher H, Teruya-Feldstein J, Shaffer D, Lis E, Abrey L. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). *J Neurooncol.* 2008 Nov 19.

Kreisl T, Panageas K, Elkin E, DeAngelis L, Abrey L. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma. *Leuk Lymphoma.* 2008 Sep;49(17):1710-6.

Kreisl T, Toothaker T, Karimi S, DeAngelis L. Ischemic stroke in patients with primary brain tumors. *Neurology.* 2008 Jun 10;70(24):2314-20.

Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK; Cintredekin Besudotox Intraparenchymal Study Group. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the Cintredekin Besudoctox Intraparenchymal Study Group. *J Clin Oncol.* 2007 Mar 1;25(7):837-44.

Kushner B, La Quaglia M, Kramer K, Modak S, Cheung N. Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. *Pediatr Blood Cancer.* 2008 Oct;51(4):552-4.

Lamborn K, Yung W, Chang S, Wenn P, Cloughesy T, DeAngelis L, Robins H, Lieberman F, Fine H, Fink K, Junck L, Abrey L, Gilbert M, Mehta M, Kuhn J, Aldape K, Hibberts J, Peterson P, Pardos M, North American Brain Tumor Consortium. Progression-free survival: An important end point.
in evaluating therapy grade gliomas. *Neuro Oncol.* 2008 Apr;10(2):162-70.

Lassman AB, Abrey LE. Should patients with anaplastic oligodendrogial tumors receive adjuvant chemotherapy? *Nat Clin Pract Oncol.* 2007 Feb;4(2):78-9.

Lassman AB, Holland EC. Incorporating molecular tools into clinical trials and treatment for gliomas? *Curr Opin Neurol.* 2007 Dec;20(6):708-11.

Lauffer I, Engel M, Feldstein N, Souweidane M. Chiari malformation presenting as a focal motor deficit. Report of two cases. *J Neurosurg Pediatrics.* 2008 May;1(5):392-9.

Law M, Brodsky JE, Babb J, Rosenblum M, Miller DC, Zagzag D, Gruber ML, Johnson G. High cerebral blood volume in human gliomas predicts deletion of chromosome 1p. Preliminary results of molecular studies in gliomas with elevated perfusion. *J Magn Reson Imaging.* 2007 Jun;25(6):1113-9.

Law M, Young RJ, Babb J, Pollack E, Johnson G. Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas. *AJNR Am J Neuroradiol.* 2007 Apr;28(4):761-6.

Law M, Young R, Babb J, Peccerelli N, Chheang S, Gruber M, Miller D, Golfinos J, Zagzag D, Johnson G. Gliomas: Predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. *Radiology.* 2008 May;247(2):490-9.

Lee G, Kim H, Elbaket Y, AlShamy G, Pangiotakos G, Barberi T, Tabar V, Studer L. Isolation and directed differentiation of human ES cell-derived neural crest stem cells. *Nat Biotechnol.* 2007 Dec;25(12):1468-75.

Lee H, Shamy GA, Elbaket Y, Schofield CM, Harrison NL, Panagiotakos G, Socci ND, Tabar V, Studer L. Directed differentiation and transplantation of human embryonic stem cell-derived motoneurons. *Stem Cells.* 2007 Aug;25(8):1931-9.

Levy O, DeAngelis LM, Filippa DA, Abrey LE. Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. *Cancer.* 2008 Jan;112(1):151-6.

Li F, Tiede B, Massagué J, Kang Y. Beyond tumorigenesis: Cancer stem cells and metastasis. *Cell Res.* 2007 Jan;17(1):3-14.

Lis E, Greenfield B, Henry M, Guilé JM, Dougherty G. Neuroimaging and genetics of borderline personality disorder: a review. *J Psychiatry Neurosci.* 2007 May;32(3):162-73.

Lo SS, Chang EL, Yamada Y, Sloan AE, Suh JH, Mendel E. Stereotactic radiosurgery and radiation therapy for spinal tumors. *Expert Rev Neurother.* 2007 Jan;7(1):85-93.

Lu H, Pollack E, Young R, Babb J, Johnson G, Zagzag D, Jensen J, Helpern J, Law M. Predicting grade of cerebral glioma using vascular-space-occupancy MRI. *AJNR Am J Neuroradiol.* 2008 Feb;29(2):373-8.

Luther N, Blisky M, Hartl R. Giant cell tumor of the spine. *Neurosurg Clin N Am.* 2008 Jan;19(1):49-55.

Luther N, Cheung N, Dunkel I, Fraser J, Edgar M, Gutin P, Souweidane M. Intraparenchymal and intratumoral interstitial infusion of anti-glioma monoclonal antibody 8H9. *Neurosurgery.* 2008 Dec;63(6):1166-74; discussion 1174.

Lyustikman Y, Momota H, Pao W, Holland E. Constitutive activation of Raf-1 induces glioma formation in mice. *Neoplasia.* 2008 May;10(5):501-10.

Martin ES, Tonon G, Sinha R, Xiao Y, Feng B, Kimmelman AC, Protopopov A, Ivanova E, Brennan C, Montgomery K, Kucherlapati R, Bailey G, Redston M, Chin L, DePinho RA. Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. *Cancer Res.* 2007 Nov 15;67(22):10736-43.

Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O’Neil J, Gutierrez A, Ivanova E, Perna I, Lin E, Mani V, Jiang S, McNamara K, Zaghluil S, Edkins S, Stevens C, Brennan C, Martin ES, Wiedemeyer R, Kabbarah O, Nogueira C, Histen G, Aster J, Mansour M, Duke V, Foroni L, Fielding AK, Goldstone AH, Rowe JM, Wang Y, Look AT, Stratton MR, Chin L, Futreal PA, DePinho RA. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. *Nature.* 2007 Jun 21;447(7147):966-71.

Matushansky I, Hernando E, Socci ND, Mills JE, Matos TA, Edgar MA, Singer S, Maki RG, Cordon-Cardo C. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. *J Clin Invest.* 2007 Nov;117(11):3248-57.

McConville P, Hambardzumyan D, Moody JB, Leopold WR, Kreger AR, Wooliscroft MJ, Rehemtulla A, Ross BD, Holland EC. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. *Clin Cancer Res.* 2007 May 15;13(10):2897-904.
To refer a patient to the Brain Tumor Center, please call 212-639-6661 or e-mail btc@mskcc.org

BRAIN TUMOR CENTER MEMBERS

Developmental Biology

Lorenz Studer, MD
Alexandra Joyner, PhD
Songhai Shi, PhD

Molecular Biology

Andrew Koff, PhD
John Petrini, PhD

Molecular Pharmacology and Chemistry

Hakim Djaballah, PhD

Mei J, Pasternak GW. Modulation of brainstem opiate analgesia in the rat by sigma 1 receptors: a microinjection study. J Pharmacol Exp Ther. 2007 Sep;322(3):1278-85.

Mellinghoff IK. Why do cancer cells become “addicted” to oncogenic epidermal growth factor receptor? PLoS Med. 2007 Oct;4(10):1620-2.

Mellinghoff IK, Cloughesy TF, Mischel PM. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):378-81.

Miyagawa T, Gogiberidze G, Srganova I, Cai S, Balaton J, Thaler H, Ageyeva L, Pillarsetty N, Finn R, Blasberg R. Imaging of HSV-tk Reporter gene expression: comparison between [18F]FEAU, [18F]FFEAU, and other imaging probes. J Nucl Med. 2008 Apr;49(4):637-48.

Modak S, Pandit-Taskar N, Kushnir BH, Kramer K, Smith-Jones P, Larson S, Cheung NK. Transient sialoadenitis: A complication of [131I]-metaiodobenzylguanidine therapy. Pediatr Blood Cancer. 2008 Jun;50(6):1271-3.

Mohile N, Abrey LE. Primary central nervous system lymphoma. Semin Radiat Oncol. 2007 Jul;17(3):223-9.

Miyagawa T, Gogiberidze G, Srganova I, Cai S, Balaton J, Thaler H, Ageyeva L, Pillarsetty N, Finn R, Blasberg R. Imaging of HSV-tk Reporter gene expression: comparison between [18F]FEAU, [18F]FFEAU, and other imaging probes. J Nucl Med. 2008 Apr;49(4):637-48.

Panagiotakos G, Alshamy G, Chan B, Abrams R, Greenberg E, Saxena A, Bradbury M, Edgar M, Gutin P, Tabar V. Long-term impact of radiation on the stem cell and oligodendrocyte precursors in the brain. PLoS ONE. 2007 Jul 11;2(7):e588.

Moroz MA, Srganova I, Zanconico P, Ageyeva L, Beresten T, Dyomina E, Burnazi E, Finn RD, Doubravin M, Blasberg RG. Imaging hNET reporter gene expression with 124I-MIBG. J Nucl Med. 2007 May;48(5):827-36.

Molecular Pharmacology and Chemistry

Hakim Djaballah, PhD

Moskowitz A, Nolan C, Lis E, Castro-Malaspina H. Perales MA. Posterior reversible encephalopathy syndrome due to sirolimus. Bone Marrow Transplant. 2007 May;39(10):653-4.

Mussak EN, Holodny AI, Karimi S. Meningioma of the mandible: Imaging with computed tomography. AJNR Am J Neuroradiol. 2007 Jun-Jul;28(6):1157-9.

Narayana A, Chang J, Thakur S, Huang W, Karimi S, Hou B, Kowalski A, Perera G, Holodny A, Gutin PH. Use of MR spectroscopy and functional imaging in the treatment planning of gliomas. Br J Radiol. 2007 May;80(953):347-54.

Navi BB, DeAngelis LM, Segal AZ. Multifocal strokes as the presentation of occult lung cancer. J Neurooncol. 2007 Dec;85(3):307-9.

Nguyen TD, Abrey LE. Brain metastases: old problem, new strategies. Hematol Oncol Clin North Am. 2007 Apr;21(2):369-88.

Nguyen T, Abrey LE. Intracranial hemorrhage in patients treated with bevacizumab and low molecular weight heparin. Clin Adv Hematol Oncol. 2007 May;5(5):375-6.

Omuro A, Delattre J. Brain tumors and dementia. Handb Clin Neurol. 2008;89:877-86.

Omuro A. Exploring multi-targeting strategies for the treatment of gliomas. Curr Opin Investig Drugs. 2008 Dec;9(12):1287-95.

Panagiotakos G, Alshamy G, Chan B, Abrams R, Greenberg E, Saxena A, Bradbury M, Edgar M, Gutin P, Tabar V. Long-term impact of radiation on the stem cell and oligodendrocyte precursors in the brain. PLoS ONE. 2007 Jul 11;2(7):e588.

Panagiotakos G, Tabar V. Brain tumor stem cells. Curr Neurol Neurosci Rep. 2007 May;7(3):215-20.

Parathath S, Mainwaring L, Fernandez-L A, Campbell D, Kenney A. Insulin receptor substrate 1 is an effector of sonic hedgehog mitogenic signaling in cerebellar neural precursors. Development. 2008 Oct;135(19):3291-300.

Pasternak GW. When it comes to opiates, just say NO. J Clin Invest. 2007 Nov;117(11):3185-7.
To refer a patient to the Brain Tumor Center, please call 212-639-6661 or e-mail btc@mskcc.org

Perry A, Miller R, Gujrati M, Scheithauer B, Casavilca Zambrano S, Jost S, Raghavan R, Qian J, Cochran E, Huse J, Holland E, Burger P, Rosenblum M. Malignant gliomas with primitive neuroectodermal tumor-like components (MG-PNET). A clinicopathologic and genetic study of 53 cases. Brain Pathol. 2009 Jan;19(1):81-90.

Placantonakis D, Laufer I, Wang J, Beria J, Boland P, Bilsky M. Posterior stabilization strategies following resection of cervicothoracic junction tumors: review of 90 consecutive cases. J Neurosurg Spine. 2008 Aug;9(2):111-9.

Placantonakis D, Tomishima M, Lafaille F, Desbordes S, Jia F, Socci N, Viale A, Lee H, Harrison N, Tabar V, Studer L. BAC transgenesis in human ES cells as a novel tool to define the human neural lineage. Stem Cells. 2008 Dec 11.

Polydorides AD, Rosenblum MK, Edgar MA. Metastatic renal cell carcinoma to hemangioblastoma in von Hippel-Lindau disease. Arch Pathol Lab Med. 2007 Apr;131(4):641-5.

Raizer J, Hwu W, Panageas K, Wilton A, Baldwin D, Bailey E, von Althann C, Lamb L, Alvarado G, Bilsky M, Gutin P. Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features. Neuro Oncol. 2008 Apr;10(2):199-207.

Rosenblum MK. The 2007 WHO classification of nervous system tumors. Newly recognized members of the mixed glioneuronal group. Brain Pathol. 2007 Jul;17(3):308-13.

Rubenstein JL, Fridlyand J, Shen A, Karch J, Abrey LE, Wang E, Haqq C, Woods C, Damon L, Prados M, McDermott M, O’Brien J, O’Connor P, Combs D, Shuman M. Phase I study of intraventricular administration of rituximab in patients with recurrent intraocular and CNS lymphoma. J Clin Oncol. 2007 Apr 10;25(11):1350-6. Epub 2007 Feb 20.

Ruff I, Brennan N, Peck K, Hou B, Tabar V, Brennan C, Holody NY A. Assessment of the language laterality index in patients with brain tumor using functional MR imaging: effects of thresholding, task selection, and prior surgery. AJNR Am J Neuroradiol. 2008 Mar;29(3):528-35.

Safdieh J, Mead P, Sepkowitz K, Kiehn T, Abrey L. Bacterial and fungal meningitis in cancer patients. Neurology. 2008 Mar 18;70(12):943-7.

Sanchez-Pernaute R, Lee H, Patterson M, Reske-Nielsen C, Yoshizaki T, Sonntag K, Studer L, Isacson O. Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson’s disease. Brain. 2008 Aug;131(Pt 8):2127-39.

Serganova I, Ponomarev V, Blasberg R. Human reporter genes: potential use in clinical studies. Nucl Med Biol. 2007 Oct;34(7):791-807.

Sgaier SK, Lao Z, Villanueva MP, Berenshtein F, Stephen D, Turnbull RK, Joyner AL. Genetic subdivision of the tectum and cerebellum into functionally related regions based on differential sensitivity to the dosage of engrailed genes. Development. 2007 Jun;134(12):2325-35.

Shah GD, Silver SJ, Gavrilovic I, Abrey LE, Lassman AB. Myelosuppression in patients benefiting from imatinib with hydroxyurea for malignant gliomas. J Neurooncol. 2007 Nov;85(2):217-22.

Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007 Oct 20;25(30):4730-5.

Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, Sawyers CL. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA. 2007 Mar 27;104(13):5563-8.

Shmelkov S, Butler J, Hooper A, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin D, Chadburn A, Murphy A, Valenzuela D, Gale N, Thurston G, Yancopoulos G, D’Angelica M, Kemeny N, Lyden D, Rafii S. CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. J Clin Invest. 2008 Jun;118(6):2111-20.

Sillitoe RV, Joyner AL. Morphology, molecular codes and circuitry produce the three dimensional complexity of the cerebellum. Annu Rev Cell Dev Biol. 2007;23:549-77.

Sillitoe R, Stephen D, Lao Z, Joyner A. Engrafted homeobox genes determine the organization of Purkinje cell sagittal stripe gene expression in the adult cerebellum. J Neurosci. 2008 Nov 19;28(47):12150-62.

Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Société Française de Greffe de Moëlle
To refer a patient to the Brain Tumor Center, please call 212-639-6661 or e-mail btc@mskcc.org
GLIOMAS

A Pharmacokinetic and Phase II Study of Sunitinib Malate in Recurrent Malignant Gliomas. Pt: Abrey, Lauren, MD [Protocol 07-153]

A Phase I Study of XL765 in Combination with Temozolomide in Patients with Malignant Gliomas. Pt: Omuro, Antonio, MD [Protocol 08-057]

A Phase II Trial of Continuous Low-Dose Temozolomide for Patients with Recurrent Malignant Glioma. Pt: Abrey, Lauren, MD [Protocol 07-064]

A Phase II Trial of Intensive Chemotherapy & Autotransplantation in Patients with Newly Diagnosed Anaplastic Oligodendroglioma. Pt: Abrey, Lauren, MD [Protocol 02-089]

Clinical Trials

Wyckoff C, Lam B, Brathwaite C, Biegel J, McKeown C, Rosenblum M, Allewell H, Sandberg D. Atypical teratoid/rhabdoid tumor arising from the third cranial nerve. J Neuroophthalmol. 2008 Sep;28(3):207-11.

Xu J, Xu M, Hurd Y, Pasternak G, Pan Y. Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene, OPRM1. J Neurochem. 2008 Dec 10.

Yamada Y, Lovelock M, Bilsky M. A review of image-guided intensity-modulated radiotherapy for spinal tumor. Neurosurgery. 2007 Aug;61(2):226-35.

Yamada Y, Bilsky M, Lovelock D, Venkatraman E, Toner S, Johnson J, Zatcky J, Zelefsky M, Fuks Z. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spine lesions. Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):484-90.

Yoffe R, Khakoo Y, Dunkel IJ, Souweidane M, Lis E, Sklar C. Recurrent ependymoma treated with high-dose tamoxifen in a peripubertal female: Impact on tumor and the pituitary-ovarian axis. Pediatr Blood Cancer. 2007 Oct 15;49(5):758-60.

Yoshida A, Sen C, Asa S, Rosenblum M. Composite pituitary adenoma and craniopharyngioma. An unusual tumor with divergent differentiation. Am J Surg Pathol. 2008 Nov;32(11):1736-41.

Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson D, Yong W, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner D, Mellinghoff I, Horvath I, Cavenee W, Cloughesy T, Mischel P. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res. 2008 Jan 15;14(2):488-93.

Young RJ, Law M, Babb J, Pollack E, Johnson G. Comparison of region of interest analysis with three different histogram analysis methods in the determination of perfusion metrics in cerebral gliomas. J Magn Reson Imaging. 2007 Oct;26(4):1053-63.

Zhang L, Lee KC, Bhojani MS, Khan AP, Shilman A, Holland EC, Ross BD, Rehemtulla A. Molecular imaging of Akt kinase activity. Nat Med. 2007 Sep;13(9):1114-9.
Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas. PI: Lassman, Andrew, MD [Protocol 06-044]

**PRIMARY CENTRAL NERVOUS SYSTEM (CNS) LYMPHOMA**

A Phase II Study of Rituximab, Methotrexate, Procarbazine and Vinristine Followed by High-Dose Chemotherapy with Autologous Stem Cell Rescue in Newly Diagnosed Primary CNS Lymphoma. Pt: Abrey, Lauren, MD [Protocol 04-129]

A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose Radiotherapy for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma. Pt: Abrey, Lauren, MD [Protocol 01-146]

**BRAIN METASTASIS**

A Phase II Study of Intrathecal I131-3F8 in Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms. Pt: Kramer, Kim, MD [Protocol 05-122]

A Phase II Trial of Patupilone in Patients with Brain Metastases from Breast Cancer. Pt: Seidman, Andrew, MD [Protocol 07-036]

Phase II Study of Patupilone (EPO906) to Treat Recurrent or Progressive Brain Metastases in Patients with Non-Small Cell Lung Cancer. Pt: Abrey, Lauren, MD [Protocol 05-085]

**PEDIATRIC TUMORS**

A Phase III Study of Intensive Induction Chemotherapy with or without Methotrexate Followed by Consolidation Therapy with Stem Cell Rescue in Young Children Newly Diagnosed with Supratentorial PNET or High-Risk Medulloblastoma. Pt: Gilheeney, Stephen, MD [Protocol 07-170]

A Phase I Study of Intrathecal Radioimmunotherapy Using 131I-8H9 for Central Nervous System/Leptomeningeal Cancers. Pt: Kramer, Kim, MD [Protocol 03-133]

Radiotherapy Alone versus Chemotherapy Followed by Response-Based Radiotherapy for Newly Diagnosed Primary CNS Germinoma. Pt: Dunkel, Ira, MD [Protocol 07-167]

A Phase II Study of Intrathecal I131-3F8 in Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms. Pt: Kramer, Kim, MD [Protocol 05-122]

A Phase II Study of Motexafin-Gadolinium and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood. Pt: Dunkel, Ira, MD [Protocol 07-140]

A Phase III Study Assessing Carboplatin and/or Isotretinoin plus Radiation in Patients with Supratentorial Primitive Neuroectodermal Tumor or High-Risk Medulloblastoma. Pt: Gilheeney, Stephen, MD [Protocol 07-174]

Phase II Study of Nimotuzumab (TheraCIM®) in Pediatric Patients with Recurrent Diffuse Intrinsic Pontine Glioma. Pt: Trippett, Tanya, MD [Protocol 08-034]

Radioimmunotherapy, Reduced-Dose External Beam Craniospinal Radiation Therapy with IMRT Boost and Chemotherapy for Patients with Standard-Risk Medulloblastoma. Pt: Dunkel, Ira, MD [Protocol 02-088]

A Phase II Study of Conformal Radiotherapy in Patients with Low-Grade Gliomas. Pt: Dunkel, Ira, MD [Protocol 07-049]

A Study of Cilengitide (EMD 121974) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma. Pt: Gilheeney, Stephen, MD [Protocol 08-143]

Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors. Pt: Becher, Oren, MD [Protocol 08-091]

**OTHER TRIALS**

A Phase II Trial of Sunitinib (Sutent®) in Patients with Recurrent or Inoperable Meningioma. Pt: Abrey, Lauren, MD [Protocol 07-135]

Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors. Pt: Correa, Denise, PhD [Protocol 04-122]

GLIOGENE: Genetic Epidemiology of Glioma International Consortium. Pt: Bernstein, Jonine, PhD [Protocol 07-137]

Reorganization of Language Function in Patients with Brain Tumors. Pt: Holodny, Andrei, MD [Protocol 05-043]
2007-2008 Additional Honors and Awards

Oren Becher
Basic Science Award (Genetically engineered brainstem glioma model), 13th ISPNO 2008

Mark Bilsky
Strathmore Who’s Who 2005–2008

*America’s Top Doctors*, Castle Connolly Guide 2005–2008

Ronald Blasberg
Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science, Society of Nuclear Medicine 2008 Annual Meeting

Cameron Brennan
ABC2 Association, research award 2005–present
Preuss Research Award, Congress of Neurological Surgeons 2008

Luca Cartegni
Bressler Scholar (Alfred W. Bressler Scholars Endowment Fund recipient) 2004–present

Lisa DeAngelis
Hopkins School Distinguished Alumna 2008

Global Directory of Who’s Who 2008

The Best Doctors in New York, 2000–2008

New York Magazine
America’s Top Doctors, Castle Connolly Guide 2000–2008

Guide to America’s Top Oncologists 2007

New York Super Doctors 2008

Best Doctors List, New York Magazine 2008

Hakim Djaballah
Robots & Vision User Recognition Award 2007

Ira Dunkel
The Best Doctors in New York, 2005–2008

New York Magazine

Kathleen Foley
League of Women Voters Women of Distinction Award 2007

Timothy Gershon
Child Neurology Society Scientific Award 2007

Hedvig Hricak
Gold Medal, Association of University Radiologists (AUR) 2007

Xeujun Jiang
Louis and Allston Boyer Young Investigator Award 2007

American Cancer Society Scholar 2007–2010

Alfred Bressler Scholar 2004–2007

Johanna Joyce
Sidney Kimmel Foundation for Cancer Research Scholar Award 2005–2007

V Foundation for Cancer Research Scholar Award 2005–2007

Rita Allen Foundation Faculty Development Award 2005–2008

Anna Kenney
The Sontag Foundation Distinguished Scientist Award 2003–2007

Handler Foundation Award for New Investigators at MSKCC 2006–2007

Alex’s Lemonade Stand Foundation for Childhood Cancer Young Investigator Award 2006-2008

Children’s Brain Tumor Foundation Award 2006–2008

Pediatric Brain Tumor Foundation Award 2007–2008

Andrew Lassman
Preuss Award in Neuro-Oncology, American Academy of Neurology 2008

David Lyden
Marquis Who’s Who in America, Marquis Who’s Who in Science and Engineering 2007

Presidential Science Award, Bial Medical Distinction Award, Pres. Silva of the Portuguese Republic 2007

Fulbright Scholarship (Beth Psaila, Marianna Papaspyridonos, research fellows) 2006–2007
| **Joan Massagué** | Award in Cancer Research, Massachusetts General Hospital | 2007 |
|-------------------|----------------------------------------------------------|------|
|                    | Passano Laureate Prize                                    | 2007 |
| **Ingo Mellinghoff** | Sontag Foundation Distinguished Scientist                  |      |
| **Stephen Nimer**  | G & P Foundation “Angel of Hope” Award                    | 2007 |
| **Marc Rosenblum** | America’s Top Doctors, Castle Connolly Guide              | 2008 |
|                    | Guide to America’s Top Pathologists                       | 2008 |
| **Charles Sawyers**| Emil J. Freireich Award                                   | 2007 |
| **Songhai Shi**    | Klingenstein Fellowship Award                             | 2007 |
|                    | March of Dimes Defects Foundation                           |      |
|                    | Basil O’Connor Starter Scholar                             | 2007 |
|                    | NARSAD Young Investigator                                   | 2008 |
|                    | Whitehall Foundation Award                                 | 2007 |
|                    | DANA Foundation Award                                       | 2007 |
| **Bhuvanesh Singh**| Teacher of the Year Award – Otolaryngology                 | 2007 |
|                    | Cornell-Columbia Program                                    |      |
| **Mark Souweidane**| Lehman Brothers Foundation Award                           | 2006–2009 |
|                    | Children’s Hope Award                                       | 2007 |
|                    | Clinical & Translational Science Center                    | 2008 |
|                    | Pilot Award                                                |      |
| **America’s Top Doctors** | (New York Metro Area) Castle Connolly Guide                       | 2008 |

**Lorenz Studer**

Semifinalist, Howard Hughes Medical Institute Investigator Competition | 2008

**Viviane Tabar**

ALS Association | 2006–2007

**Suzanne Wolden**

Best Doctors in America, Best Doctors, Inc. | 2007

**Yoshiya Yamada**

Distinguished Award for Teaching, MSKCC Radiation Oncology Department | 2008

**Robert Young**

Norman E. Leeds Award, Eastern Neuroradiological Society | 2007

To refer a patient to the Brain Tumor Center, please call 212-639-6661 or e-mail btc@mskcc.org